Insights from the BKEVER Trial comparing everolimus versus mycophenolate mofetil for BK Polyomavirus infection in kidney transplant recipients
Kidney International · 2025-02 · 107 (2) · 338-347
DOI: 10.1016/j.kint.2024.09.018 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Kidney International, 2025-02. Verfasst von Sophie Caillard und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Dialysis and Transplantation, Institut National de la Santé et de la Recherche Médicale (INSERM), Immuno-Rhumatologie Moléc…. Hauptthemen laut MEDLINE: Kidney Transplantation, Everolimus, Polyomavirus Infections, Mycophenolic Acid. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
The MTOR inhibitors have demonstrated antiviral properties, and prior non-randomized studies have suggested they may have a suppressive effect on BKPyV replication. Here, in this randomized, multicenter, controlled trial (BKEVER study), we sought to evaluate the impact of everolimus (EVR) in facilitating the clearance of BKPyV compared to simply reducing immunosuppression among kidney transplant recipients (KTRs). All together, 130 KTRs presenting with BKPyV DNAemia were randomized 1:1 into two groups. The EVR group, in which mycophenolate mofetil (MMF) was replaced by EVR along with a decrease in calcineurin inhibitor trough levels and secondly the MMF group, in which the MMF dose was decreased by half along with a similar lowering of calcineurin inhibitor levels. The primary endpoint was the proportion of patients achieving viral clearance at six months. Secondary endpoints included the kinetics of BKPyV replication over time, the incidence of BKPyV-associated nephropathy, kidney graft function, the incidence of kidney graft rejection, and medication tolerability over two years. Significantly, BKPyV clearance was achieved in 55.7% of patients in the EVR group compared to 81.3% of patients in the MMF group at six months. The reduction in BKPyV DNA load was significantly more rapid in the MMF group. Calcineurin inhibitor trough levels were within expected target ranges and did not differ meaningfully between the two groups from randomization through month six. Two grafts were lost, and four patients died. Eleven patients in the EVR group and six patients in the MMF group developed biopsy-proven BKPyV nephropathy. Thus, in KTRs with BKPyV DNAemia, replacing MMF with EVR along with lowering calcineurin inhibitor levels did not lead to more frequent or faster clearance of BKPyV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Dialysis and Transplantation, Institut National de la Santé et de la Recherche Médicale (INSERM), Immuno-Rhumatologie Moléculaire (IRM) Unité Mixte de Recherche (UMR)-S 1109, Strasbourg Univers…
- Department of Public Health, Strasbourg University Hospital, Strasbourg, France.
- Department of Virology, INSERM, Immuno-Rhumatologie Moléculaire (IRM) Unité Mixte de Recherche (UMR)-S 1109, Strasbourg University Hospital, Strasbourg, France.
- Department of Nephrology and Transplantation, University of Rouen, Rouen, France.
- Department of Nephrology and Transplantation, University of Amiens, Amiens, France.
- Department of Nephrology and Transplantation, Necker University Hospital-Assistance Publique Hôpitaux de Paris (APHP), Institut Necker Enfants Malades (INEM) INSERM U 1151-Centre National de Recherche Scientifique (CNRS…
Zitieren
APA
Caillard, S., Meyer, N., Solis, M., Bertrand, D., Jaureguy, M., Anglicheau, D., Ecotiere, L., Buchler, M., Bouvier, N., Schvartz, B., Rerolle, J. P., Heng, A. E., Couzi, L., Duveau, A., Morelon, E., LeMeur, Y., Golbin, L., Thervet, E., Benotmane, I., & Fafi-Kremer, S. (2025). Insights from the BKEVER Trial comparing everolimus versus mycophenolate mofetil for BK Polyomavirus infection in kidney transplant recipients. Kidney International, 107(2), 338-347. https://doi.org/10.1016/j.kint.2024.09.018
Vancouver
Caillard S, Meyer N, Solis M, Bertrand D, Jaureguy M, Anglicheau D, et al. Insights from the BKEVER Trial comparing everolimus versus mycophenolate mofetil for BK Polyomavirus infection in kidney transplant recipients. Kidney International. 2025;107(2):338-347. doi:10.1016/j.kint.2024.09.018
BibTeX
@article{Caillard2025,
author = {Caillard, Sophie and Meyer, Nicolas and Solis, Morgane and Bertrand, Dominique and Jaureguy, Maite and Anglicheau, Dany and Ecotiere, Laure and Buchler, Matthias and Bouvier, Nicolas and Schvartz, Betoul and Rerolle, Jean Philippe and Heng, Anne Elisabeth and Couzi, Lionel and Duveau, Agnes and Morelon, Emmanuel and LeMeur, Yann and Golbin, Léonard and Thervet, Eric and Benotmane, Ilies and Fafi-Kremer, Samira},
title = {Insights from the BKEVER Trial comparing everolimus versus mycophenolate mofetil for BK Polyomavirus infection in kidney transplant recipients},
journal = {Kidney International},
year = {2025},
volume = {107},
number = {2},
pages = {338--347},
doi = {10.1016/j.kint.2024.09.018}
}
EUVIMED